Program overview

Novel Antimicrotubule Agent

  • Similar mechanism of action to taxanes, but effective in taxane-resistant cancers
    • Celgene's Abraxane (nab-paclitaxel)
      • Currently used in 50% of pancreatic cancer patients
      • Expected to generate $2.2B annually in sales by 2020
    • Taxol (paclitaxel)
    • Taxotere (docetaxel)
    • Jevtana (cabazitaxel)

Despite impressive efficacy relative to taxanes, the epothilone class drugs have stalled clinically due to toxicity


IT-147 significantly reduces the toxicity of epothilone D

  • Epothilone D (KOS-862), originally developed by Kosan and Roche, previously completed Phase 2 trials in colorectal, metastatic breast, and non-small cell lung cancers, but development was halted
  • IT-147 uses Intezyne's nanoparticle platform (IVECT) to administer up to 4x more epothilone D safely, resulting in significantly better anti-tumor efficacy in established preclinical models

IT-147 Preclinical Data


About Breast Cancer

Most prevalent cancer in the U.S., representing 15% of new cancer cases

  • First-line therapy is typically taxanes
  • 225,000 patients diagnosed annually; 40,000 deaths annually
    • 10-20% of patients are triple negative breast cancer patients
  • Triple negative breast cancer is generally more aggressive
    • 34% recurrence rate within 3 years
  • Potentially eligible for both Breakthrough Therapy and Orphan Drug Designations (triple negative breast cancer)

IT-147 Development Rationale

  • The epothilone class has demonstrated efficacy in treating taxane-resistant cancers
    • Both epothilone B and epothilone D were halted in clinical development due to safety challenges, specifically neuropathy, despite showing promising efficacy
  • In preclinical models, IT-147 delivered more (10x) epothilone D safely, significantly widening the therapeutic window
  • IT-147 could provide a compelling therapeutic alternative to patients with taxane-resistant cancers, with downstream potential as front-line therapy, driven in part by the increasing prevalence of taxane resistance